Apraclonidine 0.5% Generic Name & Formulations
Apraclonidine (as HCl) 0.5%; oph soln; contains benzalkonium chloride.
Soln 0.5%—contact supplier; 1% (0.1mL)—2
Apraclonidine 0.5% Indications
Short-term adjunctive therapy to reduce elevated IOP.
Apraclonidine 0.5% Dosage and Administration
Remove contact lenses; may reinsert 15min after instillation. 1–2 drops into affected eye(s) 3 times daily. Allow at least 5mins between instillation of other oph drugs.
Apraclonidine 0.5% Contraindications
Clonidine allergy. Concomitant MAOIs.
Apraclonidine 0.5% Boxed Warnings
Apraclonidine 0.5% Warnings/Precautions
Monitor visual fields. Severe uncontrolled cardiovascular disease, hypertension, coronary insufficiency. Recent myocardial infarction. Cerebrovascular disease. Raynaud's disease. Thromboangiitis obliterans. History of vasovagal attack. Discontinue if ocular allergic-like reactions occur. Renal or hepatic impairment: closely monitor cardiovascular parameters. Depression. May mask hypoglycemia. Pregnancy. Nursing mothers (1% soln: discontinue nursing temporarily for 1 day of use).
Apraclonidine 0.5% Pharmacokinetics
Apraclonidine 0.5% Interactions
See Contraindications. May potentiate CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Caution with TCAs, β-blockers, antihypertensives, cardiac glycosides, others (eg, clonidine). Concomitant CV drugs: monitor HR, BP periodically.
Apraclonidine 0.5% Adverse Reactions
Hyperemia, pruritus, dry mouth, itching, discomfort, tearing, dizziness, solmnolence, lid edema, blurred vision, foreign body sensation, dry eye, conjunctivitis, discharge, blanching; tachyphylaxis may develop after 1 month; also in post-laser surgery: upper lid elevation, inflammation, nasal decongestion, mydriasis, irregular HR.
Apraclonidine 0.5% Clinical Trials
Apraclonidine 0.5% Note
Apraclonidine 0.5% Patient Counseling